Two secondary analyses were conducted based on the samples from previous RCTs that examined the cardiovascular effects of GLP-1 agonists in patients with T2DM, with approximately 10,000 participants randomly assigned to either GLP-1 agonists or placebo.5 This evidence concerns the gene GLP1R and type 2 diabetes mellitus.